Gordian Group will be hosting a private investor webinar centered around ALS therapies and the merits of investing in orphan drug development.
Date: Thursday, February 20, 2020
Click here to view the speaker bios for this webinar.
The presenters of this webinar are executives from Aclipse Therapeutics, (www.aclipsetherapeutics.com) an innovative biopharmaceutical company that focuses on developing novel and highly differentiated drugs to address diseases with high unmet medical needs. Aclipse is led by a veteran biopharmaceutical team with three prior drug development success stories together and includes the top two key opinion leaders for ALS globally.
The Company’s lead candidate product (M102) represents a novel approach for treating Amyotrophic Lateral Sclerosis, more commonly known as ALS or Lou Gehrig’s disease. M102 is eligible for FDA Fast Track, Breakthrough Therapy, and Priority Review. These designations reduce costs, accelerate the timeline to bring products to market and provide market protection thereby mitigating risks associated with early-stage drug development.